Načítá se...
Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF
OBJECTIVE: The use of alemtuzumab, a humanized monoclonal anti-CD52 antibody has changed the therapy of highly active relapsing-remitting MS (RRMS). Alemtuzumab infusion depletes most lymphocytes in peripheral blood, whereas differential recovery of immune cells, probably those with a less CNS-autor...
Uloženo v:
| Vydáno v: | Neurol Neuroimmunol Neuroinflamm |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Lippincott Williams & Wilkins
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7007635/ https://ncbi.nlm.nih.gov/pubmed/31826986 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000654 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|